Arthneeti
All Q4 FY26 results →
NB

Nath Bio-Genes (India) Ltd

Q4 FY26Agricultural Food & other Products

NATHBIOGEN Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹167
Market cap₹373 Cr
P/E9.6
Updated17 Jun 2026
Read4 min read

What the Q4 FY26 call signalled

0 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexNo capex planned

The short version

- Cotton volume is expected to grow around 20%, consistent with the 22% growth achieved in FY26. - Revenue growth for FY27 is expected between 15-20%, driven by strong volume growth in cotton (22%), paddy (25%), and maize (54%).

From Nath Bio-Genes (India) Ltd's Q4 FY26 earnings-call transcript · updated 17 Jun 2026.

Revenue & Sales Performance

Moderate growth
  • Cotton volume is expected to grow around 20%, consistent with the 22% growth achieved in FY26.
  • Paddy volume growth is anticipated at 20-25%, reflecting strong performance.
  • Maize is a key growth driver, with significant volume surge of 54% in FY26 and expected to maintain strong growth.
  • Overall top-line (revenue) growth for FY27 is conservatively projected between 15-20%.
  • EBITDA margins and net profit margins are expected to maintain a slight upward trend.
  • The company is confident in scaling operations sustainably, backed by a stable production base, growing market presence, and robust product pipeline.

2 more points from Nath Bio-Genes (India) Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Nath Bio-Genes (India) Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

No capex planned
  • Nath Bio-Genes follows a conservative CapEx policy focusing mainly on land bank and vehicles necessary for sales and production.
  • The company avoids heavy investments in processing plants and storage facilities, opting instead for rentals, as the need for such infrastructure is limited and seasonal (e.g., maize requires about 15-20 days of processing).
  • For FY27, there are no significant planned CapEx investments in processing capacity, cold storage, or new geographies.
  • The strategy favors minimal CapEx with an emphasis on operational efficiency and leveraging existing external infrastructures rather than owning them.

Top-ranked in Agricultural Food & other Products

Ranked on what management guided this quarter

Guidance-ranked
1Regaal Resources
Rev 1Mar 2
2TBI Corn
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Nath Bio-Genes (India) Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript from the Q4 FY26 earnings call of Nath Bio-Genes Limited does not explicitly mention the current or expected order book or pending orders in specific numeric terms. However, some relevant points indicating the company's outlook on production, inventory, and sales order status are: - Inventory has increased as the company is building stock ahead of the upcoming season, expecting sales to liquidate the inventory over the next two years. - Production is being stabilized with improved yield, contributing to increased sales (cotton Bt volume grew 22% YoY). - The company anticipates top-line growth of 15-20% for FY27, reflecting confidence in demand.

2 more points from Nath Bio-Genes (India) Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Nath Bio-Genes (India) Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹52 Cr, net loss ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Nath Bio-Genes's management said in earlier quarters

Others in Agricultural Food & other Products this season

  • TBI Corn Ltd (Q4 FY26)

    Current capacity utilization is at 72% of 350 TPD; plans to increase utilization to 96-97% across plants, driving growth (Pages 14, 16). Key concall takeaways…

  • Uttam Sug.Mills (Q4 FY26)

    Consolidated: ₹471.87 Cr (Q4 FY26) vs ₹569.13 Cr (Q4 FY25), ↓ ~17.1% YoY . Key concall takeaways from Uttam Sugar Mills Ltd's Q4 FY26 earnings call — and how…

  • GRM Overseas Ltd (Q4 FY26)

    597.2 Crores vs. Key concall takeaways from GRM Overseas Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.

  • Amir Chand Jagdish Kumar (Exports) Ltd (Q4 FY26)

    694.7 Cr . Key concall takeaways from Amir Chand Jagdish Kumar (Exports) Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Marico Ltdvs Tata Consumer Products Ltdvs Patanjali Foods Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Nath Bio-Genes (India) Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Nath Bio-Genes (India) Ltd Q1 FY27 results?

- Cotton volume is expected to grow around 20%, consistent with the 22% growth achieved in FY26. - Revenue growth for FY27 is expected between 15-20%, driven by strong volume growth in cotton (22%), paddy (25%), and maize (54%).

What is Nath Bio-Genes (India) Ltd share price analysis?

Nath Bio-Genes (India) Ltd currently shows a below-average growth signal. The stock trades at a P/E of 9.6 with a market cap of ₹372. Investors should review the full earnings analysis for detailed insights.

Is Nath Bio-Genes (India) Ltd planning capital expenditure?

- Nath Bio-Genes follows a conservative CapEx policy focusing mainly on land bank and vehicles necessary for sales and production.

Keep Nath Bio-Genes (India) Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.